GH Research (GHRS) to showcase GH001 TRD trial posters at ECNP 2025

Rhea-AI Filing Summary

GH Research PLC reports that it will present clinical data from its GH001-TRD-201 trial in treatment-resistant depression at the 38th European College of Neuropsychopharmacology (ECNP) annual meeting in Amsterdam from October 11-14, 2025.

One poster, presented by Dr. Fabian Devlin on October 13, 2025, will cover the psychoactive effects of GH001 in patients with treatment-resistant depression from a Phase 2b, double-blind, randomised controlled trial. A second poster, presented by Prof. Bernhard T. Baune on October 14, 2025, will address safety and tolerability results from the same Phase 2b, double-blind trial with an open-label extension of GH001 in treatment-resistant depression.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

Commission File Number: 001-40530

GH Research PLC

(Exact name of registrant as specified in its charter)

Joshua Dawson House

Dawson Street

Dublin 2

D02 RY95

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F

GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38^th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands.

A copy of the poster to be presented by Dr. Fabian Devlin during Poster Session 3 on October 13, 2025, is attached hereto as Exhibit 99.1.

A copy of the poster to be presented by Prof. Bernhard T. Baune during Poster Session 4 on October 14, 2025, is attached hereto as Exhibit 99.2.

1

EXHIBIT INDEX

99.1	Poster to be presented by Dr. Fabian Devlin with Title: Psychoactive Effects of GH001 in Patients With Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomised Controlled Trial
99.2	Poster to be presented by Prof. Bernhard T. Baune with Title: Safety and Tolerability Results From a Phase 2b, Double-Blind Trial With an Open-Label Extension of GH001 in Treatment-Resistant Depression

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GH Research PLC
Date: October 10, 2025
	By:	/s/ Julie Ryan
	Name:	Julie Ryan
	Title:	Vice President, Finance

3

FAQ

What did GH Research PLC (GHRS) disclose in this 6-K filing?

GH Research PLC disclosed that it will present data from its GH001-TRD-201 clinical trial in treatment-resistant depression at the 38th ECNP annual meeting in Amsterdam in October 2025.

What is the focus of GH Research PLC's GH001-TRD-201 trial posters?

One poster focuses on the psychoactive effects of GH001 in patients with treatment-resistant depression, and another covers safety and tolerability results from a Phase 2b, double-blind trial with an open-label extension.

When and where will GH Research PLC present the GH001-TRD-201 data?

The data will be presented at the 38th ECNP annual meeting in Amsterdam, the Netherlands, which is scheduled for October 11-14, 2025.

Who will present the GH001 posters for GH Research PLC?

Dr. Fabian Devlin will present a poster during Poster Session 3 on October 13, 2025, and Prof. Bernhard T. Baune will present a poster during Poster Session 4 on October 14, 2025.

What type of trial is GH001-TRD-201 for treatment-resistant depression?

GH001-TRD-201 is described as a Phase 2b, double-blind, randomised controlled trial with an open-label extension in patients with treatment-resistant depression.